publication venue for Hypomethylating agents-venetoclax as salvage therapy for relapse of AML and MDS after allogeneic HCT.. 3:-. 2026 Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemia.. 2:-. 2025
